South Carolina's 50,000-Person Genetic Screening Initiative Reveals How Population Genomics Can Achieve Health Equity at Scale

South Carolina has accomplished what many public health experts considered nearly impossible: deploying a statewide genetic screening program that reaches rural communities and socially vulnerable populations with the same effectiveness as affluent urban centers. The "In Our DNA SC" initiative, administered by the Medical University of South Carolina in partnership with genomics company Helix, has enrolled 50,000 adults across all 46 counties to screen for three inherited conditions that can be prevented or managed with early intervention.

The program's achievement lies in demonstrating that population genomics can overcome the equity barriers that have plagued precision medicine since its inception. By offering three collection methods—clinic blood draws, community events partnered with churches and health systems, and at-home saliva kits—the initiative maintained consistent participation rates across urban and rural areas when adjusted for population size, including communities classified by the CDC as socially vulnerable.

Detecting Actionable Risks Before Symptoms Emerge

The program screens for three conditions on the CDC's list of medically actionable genetic disorders: hereditary breast and ovarian cancer (BRCA variants), Lynch syndrome, and familial hypercholesterolemia. These conditions have proven interventions that can prevent disease when identified early.

Approximately 1 in 60 to 65 participants (1.5-1.7%) have been identified as carrying treatable inherited disease risks. For these individuals, genetic results return to their medical records within weeks, accompanied by free genetic counseling services. This represents a fundamental shift from reactive genetic testing—conducted after diagnosis or in response to family history—to proactive population-level screening that identifies at-risk individuals decades before symptoms might appear.

The conditions targeted carry significant preventive potential. BRCA carriers can pursue enhanced surveillance or risk-reducing surgeries that dramatically lower cancer incidence. Lynch syndrome identification enables colonoscopy screening protocols that catch cancers at treatable stages. Familial hypercholesterolemia detection allows for aggressive cholesterol management that prevents early cardiovascular disease.

Building the Infrastructure for Genomic Public Health

Helix's role as the sequencing partner positions the company at the forefront of an emerging market: state-level genomic screening programs. While the company built its reputation in direct-to-consumer testing, this partnership demonstrates the scalability of its platform for public health applications and creates a replicable model for other states considering similar initiatives.

The competitive implications extend beyond Helix. Companies like Illumina, 23andMe, Color Health, and Invitae now face pressure to develop comparable public health infrastructure and demonstrate equitable reach across diverse populations. The South Carolina model suggests that the future of genomics may lie not in consumer-driven testing, but in government-partnered population screening programs that integrate genetic risk assessment into routine primary care.

For healthcare systems, the program signals a coming transformation. Primary care providers will increasingly need to integrate genomic risk assessment into standard practice, creating demand for genetic counseling services and preventive care pathways for patients identified with inherited risks. The deidentified database generated by the program also provides research infrastructure for understanding genetic variation across diverse populations—a critical need for improving the clinical utility of genomic testing beyond populations of European ancestry.

Sources

1. DNA Screening In Every Corner Of South Carolina — Forbes